Related Experiment Videos
Mitolactol chemotherapy for malignant melanoma: a phase II study
Cancer Treatment Reports
|July 1, 1984
Summary
Mitolactol showed limited efficacy in malignant melanoma patients. Objective tumor responses were observed only in those previously treated with dacarbazine, suggesting a potential role in pre-treated populations.
Area of Science:
- Oncology
- Pharmacology
Background:
- Malignant melanoma is a significant public health concern.
- Dacarbazine is a standard chemotherapy for melanoma.
- Novel therapeutic agents are needed for melanoma treatment.
Purpose of the Study:
- To evaluate the efficacy of mitolactol in malignant melanoma patients.
- To assess response rates in a pre-treated population.
Main Methods:
- Fifty-one patients with malignant melanoma were enrolled.
- Forty-three patients were evaluable for response.
- Mitolactol was administered in an intermittent oral schedule.
Main Results:
- Four objective tumor responses were observed.
- All responses occurred in patients previously treated with dacarbazine.
- Mitolactol demonstrated limited activity in this cohort.
Conclusions:
- Mitolactol has minimal efficacy as a single agent in malignant melanoma.
- Prior dacarbazine treatment may be a predictive factor for mitolactol response.
- Further investigation in specific patient subgroups is warranted.